MB-CART2019.1
Sponsors
Miltenyi Biomedicine GmbH
Conditions
Acute Lymphatic LeukemiaB-cell Non Hodgkin LymphomaCAR T Cell TherapyChildhood Non-Hodgkin LymphomaChronic Lymphatic LeukemiaDLBCL - Diffuse Large B Cell LymphomaDiffuse Large B-cell LymphomaMelanoma Stage III
Phase 1
Phase 2
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Active, not recruitingNCT04844866
Start: 2021-08-18End: 2031-09-30Updated: 2025-12-24
A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation
Active, not recruitingCTIS2023-506270-13-00
Start: 2021-07-27Target: 214Updated: 2026-01-14
A multi-center single arm Phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma
Not yet recruitingCTIS2023-508508-39-01
Target: 4Updated: 2024-07-01
A single-arm, multi-center, open-label Phase II study to determine the safety and efficacy of MB-CART2019.1 in pediatric subjects with relapsed/refractory (r/r) mature B-cell neoplasms who have relapsed after one or more prior therapies, including subjects with primary refractory disease
RecruitingCTIS2023-506348-17-00
Start: 2025-07-22Target: 12Updated: 2025-09-29
DALY II Japan/MB-CART2019.1 for DLBCL
RecruitingNCT07288879
Start: 2025-12-11End: 2028-12-31Target: 31Updated: 2026-01-08